Aelis Farma Takes Part in the 10th Edition of the Gordon Research Conference on the Role of Cannabinoid Receptors in Central Nervous System Disorders

Regulatory News:

Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces its participation in the 10^th Gordon Research Conference (GRC), taking place from July 16 to 21, 2023 in Barcelona, Spain.

The GRC is a leading international scientific conference that aims to advance the frontiers of science through the presentation of cutting-edge research, with a focus on interaction between scientists from different specialties. The conference programme includes a wide range of speakers, institutions and organisations from around the world, focusing on the latest developments in the field.

The programme for this 10^th edition is based around the central theme of the neurobiology of cannabinoids: "Charting the Course to Novel Therapeutics from a Fundamental Understanding of Cannabinoid Neurobiology".

Pier Vincenzo Piazza, CEO of Aelis Farma, took part in a plenary session on Tuesday, July 18, to present the innovative approach developed by Aelis Farma for the treatment of cognitive disorders, based on "specific-signaling" inhibition of the CB₁ cannabinoid receptor: "Signaling Specific Inhibitors of the CB1R as a New Approach for the Treatment of Cognitive Impairments".

“It has been a great honour to present to the scientists at the Gordon Conference on cannabinoids our recent work with AEF0217 on cognitive disorders in Down syndrome and in certain autism spectrum disorders such as Phelan-McDermid Syndrome. AEF0217 is the second drug candidate of our new pharmacological class, CB₁-SSi. Discovered and developed by scientists at Aelis Farma, CB₁-SSi appear to be able of selectively inhibiting the activity of the CB₁ receptor involved in pathological states, without interfering with its normal physiological activity. AEF0217, currently in phase 1/2 clinical trials in people with Down syndrome, could become the first treatment for the cognitive deficits associated with this condition. AEF0217 could also help patients suffering from autism spectrum disorders, considerably expanding the fields of application of this drug candidate”, stated Pier Vincenzo Piazza.